Blog

The Alliance’s blog offers a personal, inside look at our activities and perspectives on a range of timely issues. We encourage your feedback.

BACK TO BLOG

Author: Noel Lloyd

Date: March 4th, 2015

Type: Blog Post

We wanted to share our reaction to communication from the U.S. Food and Drug Administration regarding updates to the labeling of prescription testosterone products. Below are excerpts from the FDA’s comments:

"The U.S. Food and Drug Administration (FDA) cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions...Testosterone is FDA-approved as replacement therapy only for men who have low testosterone levels due to disorders of the testicles, pituitary gland, or brain that cause a condition called hypogonadism. Examples of these disorders include failure of the testicles to produce testosterone because of genetic problems, or damage from chemotherapy or infection. However, FDA has become aware that testosterone is being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging. The benefits and safety of this use have not been established."

Our president & CEO Susan Peschin offered the following statement about the FDA’s comments:

“While we agree that the FDA got it right when they asked makers of testosterone products to include a label statement on safety and efficacy, the extra language they requested on defining hypogonadism is unintentionally ageist. The Alliance for Aging Research believes that the FDA should wait on the results of the required five-year study in the older adult population before mandating additional language. In this case, less really is more.”






A Tribute to a Great Scientist

Author: Dan Perry

Date: March 11th, 2008

FDA Needs More Funding to Fulfill Its Mission

Author: Cynthia Bens

Date: March 18th, 2008

Spending or Investing? -- The Silver Book & Innovation

Author: Lindsay Clarke

Date: March 26th, 2008

Preventing the Flu: A Q & A with Dr. William Schaffner

Author: Noel Lloyd

Date: December 4th, 2017

A Recap of the Clinical Trials for Alzheimer’s Disease Conference

Author: Phyllis Greenberger

Date: December 1st, 2017

An Update on the Clinical Trials for Alzheimer’s Disease Conference

Author: Noel Lloyd

Date: November 7th, 2017

Living Longer & Loving It

Sign up for our electronic newsletter Living Longer & Loving It